Document is current
Any future updates will be listed below
-
Authors
Ferber, Dyke
Wölflein, Georg https://orcid.org/0000-0002-0407-7617
Wiest, Isabella C.
Ligero, Marta
Sainath, Srividhya
Ghaffari Laleh, Narmin https://orcid.org/0000-0003-0889-3352
El Nahhas, Omar S. M.
Müller-Franzes, Gustav
Jäger, Dirk
Truhn, Daniel
Kather, Jakob Nikolas https://orcid.org/0000-0002-3730-5348
- License Information
-
More Information
Article History
Received: 13 January 2024
Accepted: 5 August 2024
First Online: 21 November 2024
Competing interests
: The authors declare the following competing interests. O.S.M.E.N. holds shares in StratifAI GmbH. J.N.K. declares consulting services for Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK, and Scailyte, Basel, Switzerland; furthermore J.N.K. holds shares in Kather Consulting, Dresden, Germany; and StratifAI GmbH, Dresden, Germany, and has received honoraria for lectures and advisory board participation by AstraZeneca, Bayer, Eisai, MSD, BMS, Roche, Pfizer and Fresenius. D.T. received honoraria for lectures by Bayer and holds shares in StratifAI GmbH, Germany. The remaining authors declare no competing interests.
